Irinotecan in relapsed or XXXX . Indications of activity in a phase II trial.

@entity1 @entity137 @entity2600 @entity146 @entity294 @entity2262 @entity880 @entity1893 @entity221 @entity3062
Because @entity2600 ( @entity2600 , Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity, we investigated its activity in relapsed or @entity1893 (NHLs). Irinotecan at 300 mg/m2 i.v. was administered every 21 days with intensive @entity3062 management of @entity294 . Responders received up to six treatment cycles. Of 44 registered @entity1 , 32 are evaluable for response. Seventeen @entity1 had received one previous regimen, and 15 @entity1 had received two. Disease was refractory to the regimen preceding irinotecan in 12 @entity1 . At baseline, serum @entity880 dehydrogenase levels were high in 47% (14/30), and @entity2262 levels were higher than 3.0 mg/L in 29% (8/28) of @entity1 . Responses were seen in 12 of 32 (38%) @entity1 (95% confidence interval [CI] = 21%-56%). Response rates were 43% for seven indolent (95% CI = 10%-82%), 0% for three mantle cell (95% CI = 0%-71%), 44% for 18 relapsed @entity146 (95% CI = 22%-69%), and 20% for five @entity1893 (95% CI = 1%-72%). Grade 3/4 @entity137 included myelosuppression, @entity221 , and @entity294 . Irinotecan appears active and relatively well tolerated in @entity1 with relapsed @entity146 or indolent @entity1893 . Accrual to this study is continuing for better determination of response rates in all histologic subtypes of @entity1893 .
